Table 3.

Nonrespiratory Outcomes

Hypercapnia GroupNC GroupP ValueRR (95% CI)
Mortality (%)12 (3/24)12 (3/25)1.01.04 (0.18, 6.16)
IVH (%)46 (11/24)56 (14/25).670.82 (0.43, 1.52)
IVH 3–4 (%)29 (7/24)20 (5/25).671.46 (0.47, 4.82)
Progression of IVH (%)28 (6/21)32 (8/25).940.89 (0.31, 2.43)
PVL (%)8 (2/24)8 (2/25)1.01.04 (0.11, 10.10)
ROP ≥stage II (%)4 (1/24)4 (1/25)1.01.04 (0.03, 37.75)
PDA (%)0 (0/24)12 (3/25).230 
NEC ≥II A (%)21 (5/24)8 (2/25).242.60 (0.49, 18.87)
Pneumonia/proven sepsis (%)29 (7/24)52 (13/25).180.56 (0.24, 1.23)
Length of stay (d)74 ± 2276 ± 21.78
  • IVH indicates intraventricular hemorrhage; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; PDA, patent ductus arteriosus; NEC, necrotizing enterocolitis; and CI, confidence interval.

    Progression of IVH data is reported for the patients that had a cranial ultrasound before randomization.

    Relative risk (RR) was calculated for the dichotomous outcome measures.